Please login to the form below

BeiGene

This page shows the latest BeiGene news and features for those working in and with pharma, biotech and healthcare.

BeiGene, Novartis’s PD-1 inhibitor tislelizumab hits the mark in second- or third-line NSCLC

At 12 months, the PFS rate was 23.3% for patients receiving BeiGene/Novartis’ therapy versus 5.7% in the docetaxel arm. ... added. In January, Novartis and BeiGene signed a strategic collaboration agreement for the Swiss pharma company to in-license

Latest news

Merck expands partnership with Zymeworks for multispecific antibodies

Chinese pharma BeiGene also owns the rights to Zanidatamab and ZW49 in a number of East Asian countries including China and South Korea as well as Australia and New Zealand.
FDA starts priority review of Kite’s CAR-T for mantle cell lymphoma

Other treatment options for advanced MCL include BeiGene’s recently approved BTK inhibitor Brukinsa (zanubrutinib) and AbbVie/Johnson &Johnson’s established BTK inhibitor Imbruvica (ibrutinib).
Boehringer Ingelheim to manufacture first biologic in China under new reforms

The milestone was achieved thanks to Boehringer’s collaboration with Chinese pharma company BeiGene, which included Boehringer offering manufacturing capabilities to support the launch of its monoclonal antibody tislelizumab. ... Boehringer will
BeiGene’s Brukinsa misses the mark in head-to-head Imbruvica trial

Although, BeiGene has said that Brukinsa demonstrated numerically higher VGPR rates, and improvements in safety and tolerability compared to Imbruvica. ... meaningful responses for many patients,” said Jane Huang (pictured left), chief medical officer,
AstraZeneca’s Calquence impresses in previously untreated CLL

However, there is also new competition in the lymphoma market from newcomer BeiGene – the Chinese-drugmaker recently won approval in the US for its MCL therapy Brukinsa (zanubrutinib).

More from news
Approximately 11 fully matching, plus 8 partially matching documents found.

Latest Intelligence

Chinese biotech’s global ambitions

BeiGene says it as headed off any such concens by working with well-established pharma company and contract manufacturer Boehringer Ingelheim to manufacture its drug. ... Meanwhile, BeiGene is also looking to break into the still all-important US market.
Biopharma's Future: Made in China

The rise of Chinese biopharma. One home-grown pharma company which could replicate this accomplishment is Beijing-headquartered BeiGene. ... BeiGene’s CEO John Oyler told a Goldman Sachs recent conference that a Chinese biopharma sector was ready to
Deal Watch March 2017

In particular, the third largest deal of the month is a joint venture between the research-based biotechnology company, BeiGene, which focuses on immuno-oncology, and the Guangzhou Development District. ... The agreement, worth $330m, will build BeiGene
Deal Watch table for November 2013

BeiGene / Merck. Serono. Co-development. Expansion of collaboration to include BeiGene 290 for cancer.

More from intelligence
Approximately 2 fully matching, plus 2 partially matching documents found.

Latest appointments

New hires at EMA, Gilead and BeiGene

EMA gains a new executive director, Gilead appoints a new senior vice president and BeiGene hires a new chief business exec. ... BeiGene. BeiGene has appointed Angus Grant (pictured above) as chief business executive.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Senior Account Director & Associate Director - Healthcare Ad...: Highly Competitive Salary, Bonus &Benefits

Account Management: Competitive Salary Offered

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

Medical Writer, Senior Medical Writer, Principal Medical Writer,...: Highly Competitive Salary, Bonus &Benefits

Editor & Senior Editor - Medical Communications - Home Based: Highly Competitive Salary, Bonus &Benefits

Client Services Director – London or Home Based – Medical Commun...: Highly Competitive Salary, Bonus &Benefits

Home Working Medical Copy Writer & Senior Medical Copy Write...: Highly Competitive Salary, Bonus &Benefits

Senior Content Editor - Biotechnology: Salary TBC

PMHub

Add my company

Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story: How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?: The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19: The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...